

## **Company Update**

31 January 2022

Australian internet of things (IoT) and healthcare technology company, Oakridge International Limited (ASX: OAK) ("Oakridge" or the "Company") is pleased to provide the following business update alongside its Appendix 4C Quarterly Cash Flow Report for the quarter ended 31 December 2021 (the "Period").

During the quarter the Company continued its path to focus on increasing its sales activities, the delivery of customer projects and product development to further enhance our existing product offering.

Interstate lockdowns and closures, as a result of the Covid-19 pandemic, have had an adverse impact on revenues and business development activities for the Period.

During the period the Company completed a share capital consolidation through the conversion of every 200 ordinary shares in the Company into 1 ordinary share in the Company.

The Company also announced the establishment of a Small Holding Share Sale Facility for holders whose shareholdings have a market value of less than \$500.

Due to the pandemic's adverse effect on our current business growth and earnings, the Company is seeking to expand its business and revenue base by exploring other emerging business in the technology sector focusing in on renewable energy, new energy vehicles and digital assets – specifically non-fungible assets. These activities are at an exploratory stage which may require shareholders and/or regulatory approval but there is no guarantee that the Company will enter any of these sectors. We shall keep the shareholders and the market informed if we decide to pursure any new such business or opportunity, if at all. The IoT and Healthcare sectors remain the focus of the Company.

During the Period, related party payments of \$54,498 relate to Director and Executive Officer fees.

### Healthcare Business

JCT Healthcare ("JCT"), a wholly owned subsidiary of the Company, is a provider of innovative technology solutions for the healthcare sector. JCT develops and distributes its own range of nurse call hardware and software solutions for use across multiple healthcare sectors including hospitals, aged care, disability care and supported independent living.

Strict COVID-19 protocols during the Period have continued to restrict the movement of staff within many healthcare facilities throughout the country. This has led to an impact on business development activities which has resulted in a decrease in quarterly revenues and new projects being secured.



The Company has submitted several proposals, at the request of clients, to upgrade existing facility infrastructure which we would expect, if successful, to commence towards the end of the 2022 financial year.

A "pilot room" was installed at a major metropolitan hospital to demonstrate the Company's technical capabilities, with the intent that a complete replacement Nurse Call system be installed throughout the remainder of the hospital.

The Company also completed a significant independent living project in conjunction with one of Australia leading disability providers. To bolster the company's footprint, an NDIS application was submitted to further enhance the Company's strong reputation in the disability sector.

The Company continues a concerted effort to diversify its products and capabilities. The validation of an appropriate RTLS (Remote Tracking Location System) was completed in December 2021 after a lengthy testing process. The Company expects that the RTLS technology offering will significantly enhance the Company's technical capabilities. In line with the Company's strategy to outsource technical developments, the Company is in discussion with technology partners to provide a proprietary RTLS solution.

### Legacy Issues

There has been no change since the last quarter. The final step in the remediation process for the Penola geothermal well is due to be completed in the coming quarters. Once completed, a \$100,000 security bond will be returned to the Company.

#### Others

As announced on 2 January 2020, the Company completed a A\$250,000 share placement ("Placement Agreement") with Teko International Limited (Teko). On 28 July 2020, the Company held a discussion with Teko in respect to a potential claim asserted by Teko against the Company for allegedly misrepresenting the Company's unrecorded liabilities, including the Heuresy liability payment previously disclosed, by its then directors. The Board believes that there may be some exposure to the Company in respect to the representations made by the then Board members. If the Company were to be subject to legal action that could be taken by Teko, there could be no assurance as to the outcome or the costs required to defend any such action. The Company will continue to discuss the issue with our legal advisors and negotiate with Teko to seek the most desirable outcome for the Company and its shareholders.

This announcement has been approved by the Board.

Julie Edwards Company Secretary Oakridge International Limited

## Appendix 4C

# Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity				
Oakridge International Limited				
ABN Quarter ended ("current quarter")				

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	145	372
1.2	Payments for		
	(a) research and development		
	(b) product manufacturing and operating costs	(10)	(17)
	(c) advertising and marketing	(7)	(7)
	(d) leased assets		
	(e) staff costs	(62)	(192)
	(f) administration and corporate costs		
1.3	Dividends received (see note 3)		
1.4	Interest received		
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Government grants and tax incentives		3
1.8	Other (provide details if material)		
1.9	Net cash from / (used in) operating activities	(286)	(370)

2.	Cas	sh flows from investing activities
2.1	Pay	ments to acquire or for:
	(a)	entities
	(b)	businesses
	(c)	property, plant and equipment
	(d)	investments
	(e)	intellectual property
	(f)	other non-current assets

ASX Listing Rules Appendix 4C (17/07/20) + See chapter 19 of the ASX Listing Rules for defined terms.

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities		

3.	Cash flows from financing activities
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)
3.2	Proceeds from issue of convertible debt securities
3.3	Proceeds from exercise of options
3.4	Transaction costs related to issues of equity securities or convertible debt securities
3.5	Proceeds from borrowings
3.6	Repayment of borrowings
3.7	Transaction costs related to loans and borrowings
3.8	Dividends paid
3.9	Other (provide details if material)
3.10	Net cash from / (used in) financing activities

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,294	2,378
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(286)	(370)
4.3	Net cash from / (used in) investing activities (item 2.6 above)		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)		
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of period	2,008	2,008

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,008	2,294
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,008	2,294

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	54
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
	f any amounts are shown in items 6.1 or 6.2, your quarterly activity report must includ ation for, such payments.	le a description of, and an

7.	<b>Financing facilities</b> Note: the term "facility' includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	Total financing facilities		
7.5	Unused financing facilities available at qu	arter end	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estim	ated cash available for future operating activities	\$A'000	
8.1	Net ca	sh from / (used in) operating activities (item 1.9)	(286)	
8.2	Cash and cash equivalents at quarter end (item 4.6)		2,008	
8.3	Unuse	d finance facilities available at quarter end (item 7.5)		
8.4	Total a	available funding (item 8.2 + item 8.3)	2,008	
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)		7.02	
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.			
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:			
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?			
	Answer:			
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?			
	Answer:			
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?			
	Answer:			
	Note: wi	here item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 abov	re must be answered.	

## **Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 January 2022

Authorised by: The Board (Name of body or officer authorising release – see note 4)

#### Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.